Epithelial-to-mesenchymal transition (EMT) promotes cell motility, which is important for the metastasis of malignant cells, and blocks CD95-mediated apoptotic signaling triggered by immune cells and chemotherapeutic regimens. CD95L, the cognate ligand of CD95, can be cleaved by metalloproteases and released as a soluble molecule (cl-CD95L). Unlike transmembrane CD95L, cl-CD95L does not induce apoptosis but triggers cell motility. Electron paramagnetic resonance was used to show that EMT and cl-CD95L treatment both led to augmentation of plasma membrane fluidity that was instrumental in inducing cell migration. Compaction of the plasma membrane is modulated, among other factors, by the ratio of certain lipids such as sphingolipids in the membrane. An integrative analysis of gene expression in NCI tumor cell lines revealed that expression of ceramide synthase-6 (CerS6) decreased during EMT. Furthermore, pharmacological and genetic approaches established that modulation of CerS6 expression/activity in cancer cells altered the level of C16-ceramide, which in turn influenced plasma membrane fluidity and cell motility. Therefore, this study identifies CerS6 as a novel EMT-regulated gene that has a pivotal role in the regulation of cell migration.
INTRODUCTION CD95L (also known as FasL) is a transmembrane ligand that binds to the so-called death receptor CD95 (also known as Fas/APO1). Metalloproteases can cleave CD95L to produce the soluble ligand cl-CD95L. Although transmembrane CD95L is a potent apoptosis inducer that participates in immune surveillance and tolerance (see review by Strasser et al. 1 ), cl-CD95L cannot induce apoptosis but instead triggers the motility of cancer cells and activated T lymphocytes [2] [3] [4] and aggravates inflammation. 4, 5 Binding of transmembrane CD95L to CD95 leads to formation of the death-inducing signaling complex, which contains the Fasassociated via death domain adaptor protein and caspases 8 and 10. 6 This complex has a pivotal role in the initiation of apoptotic signaling. Cells can be classified as type I or type II according to the efficiency with which death-inducing signaling complex forms and their reliance on the mitochondrion-driven apoptotic signal to implement the CD95-mediated apoptotic signal. 6 We previously showed that type II cells are of epithelial lineage, whereas type I cells are mesenchymal-like. 7 Type II cells are more sensitive to the CD95-mediated apoptotic signal than type I cells; therefore, it was concluded that cancer cells undergoing epithelialto-mesenchymal transition (EMT) reprogram their apoptotic machinery to resist CD95-mediated cell death. 7 These findings encouraged us to investigate whether EMT alters the cellular response to cl-CD95L, that is, motility. Sphingolipids (SLs) belong to a class of lipids whose members have multiple roles in eukaryotic cells. SLs are important structural components of membranes and are second messengers that regulate cell growth, differentiation and death. 8 Ceramide (N-acyl-D-erythro-sphingosine) can be generated via hydrolysis of sphingomyelin by sphingomyelinases or via ceramide synthase (CerS)-mediated de novo ceramide biosynthesis. This pathway involves acylation of sphinganine with fatty acyl-CoAs of chain lengths of C14-C26 to produce dihydroceramide. Alternatively, CerS can synthesize ceramide by the salvage pathway through direct acylation of sphingosine, which is derived from SL catabolism. 8 Ceramide synthesis is orchestrated by six mammalian CerS proteins, each of which produces ceramides with restricted acyl chain lengths. 9 Among these proteins, ceramide synthase isoform 6 (CerS6) was most recently cloned. 10 Although most studies of ceramides have analyzed their impact on apoptotic signaling, these lipids also promote the formation of ordered liquid phases called lipid rafts, whose accumulation rigidifies the plasma membrane. 11 Ceramides form rigid ceramide-enriched domains when their N-acyl chain is longer than C12 12, 13 and lead to an overall decrease in ordered lipid membranes in CerS2-null mice. 14 The biophysical properties of hepatocyte membranes are modified in CerS2-null mice, including increased fluidity, 15 which is directly associated with changes in the SL composition. Furthermore, high plasma membrane fluidity is correlated with enhanced migratory/invasive ability of tumor cells, [16] [17] [18] [19] which might be due to the enhanced deformability of these cells. 16 These observations raise the possibility that EMT alters the level of SL biosynthesis to increase membrane fluidity, which in turn promotes cell migration, a phenotypic change associated with EMT.
In this study, we demonstrate that EMT enhances CD95mediated signaling to promote cell migration. An epithelial/ mesenchymal comprehensive microarray analysis was used to show that CerS6 is differentially expressed during EMT and to provide evidence that the level of CerS6 expression controls the C16-ceramide membrane content of breast cancer cells, which in turn modulates their plasma membrane fluidity and motility.
RESULTS
EMT and cl-CD95L-induced cell migrations are correlated with increased membrane fluidity Using a transcriptomic analysis of 22 tumor cell lines of various histological origins (National Cancer Institute (NCI)) that respond differently to cytotoxic CD95L, we previously demonstrated that type I cells display a mesenchymal-like phenotype, whereas type II cells have an epithelial-like gene signature. 7 Cl-CD95L does not induce cell death but triggers cell motility; 4 therefore, we investigated whether EMT modifies the response of tumor cells to a CD95-driven pro-migratory cue. Using a Boyden chamber assay, cell motility was evaluated in various mesenchymal-and epithelial-like breast cancer cells in the presence or absence of cl-CD95L ( Figure 1a ). Although mesenchymal-like cells migrated spontaneously across pore-containing membranes in the absence of cl-CD95L, epithelial cells did not ( Figure 1a ). In addition, cl-CD95L treatment increased mesenchymal cell migration but not epithelial cell migration (Figure 1a ). This suggests that CD95mediated cell migration is blocked in the latter cells and/or promoted in the former cells.
Increased membrane fluidity can promote the invasion/motility of tumor cells; [16] [17] [18] [19] therefore, we next evaluated the membrane lipid packing densities of a large set of tumor cell lines. To this end, electron paramagnetic resonance (EPR) was used to quantify the S parameter, a biophysical parameter that is inversely correlated with membrane fluidity. 20 The S parameter was higher in epithelial tumor cells than in mesenchymal tumor cells (0.496 ± 0.0088, n = 17 versus 0.467 ± 0.0215, n = 20, P ⩽ 0.001; Figure 1b ), indicating that EMT led to membrane fluidization. Confirming this, membrane fluidity was higher in mesenchymal breast cancer cells than in epithelial breast cancer cells (0.464 ± 0.0043, n = 6 versus 0.476 ± 0.0069 n = 6, P = 0.0043; Figure 1b ). In addition, the membrane fluidity of mesenchymallike MDA-MB-231 breast tumor cells increased following cl-CD95L treatment (Figure 1c ). To determine the role of plasma membrane fluidity in cell migration, MDA-MB-231 cells were pretreated with non-cytotoxic doses of the membrane-stabilizing agent ursodeoxycholic acid (UDCA) 21 or the cyclopropyl fatty acid ester A2C, a compound that fluidifies plasma membranes. 22 Pre-incubation of MDA-MB-231 cells with UDCA slightly decreased basal membrane fluidity, although not significantly; however, this treatment abrogated the CD95-mediated increase in plasma membrane fluidity ( Figure 1c ). By contrast, A2C treatment significantly enhanced both basal and CD95-induced cell membrane fluidity (Figure 1c ). Importantly, CD95-mediated migration of MDA-MB-231 cells was completely abolished by UDCA treatment but stimulated by A2C treatment (Figure 1d ). Collectively, these data indicate that plasma membrane fluidity increases during EMT and that this biophysical parameter has a pivotal function in both EMT-driven and CD95-mediated cell motility.
EMT triggers downregulation of CerS6
Cholesterol and SLs participate in plasma membrane fluidity and compaction; therefore we next investigated whether enzymes involved in the biosynthesis of these lipids are upregulated or downregulated during EMT. To this end, a transcriptomic metaanalysis was performed using data from 22 tumor cell lines. These cell lines were epithelium-like or mesenchymal-like 23 and were previously categorized as type II and type I, respectively, based on their sensitivity to the CD95-mediated apoptotic signal. 7 Data were extracted from the NCBI Gene Expression Omnibus repository. The Significance Analysis of Microarrays tool was used to identify 168 genes that were significantly upregulated in type II cells and 542 genes that were significantly upregulated in type I cells (Supplementary Tables S1 and S2, respectively). Further analysis revealed that expression of CerS6, also known as LASS6, was significantly higher in type II (epithelial-like) cells than in type I (mesenchymal-like) cells. This in silico analysis was next validated experimentally at the mRNA (Figure 2a ). To rule out the possibility that this CerS was only associated with the way tumor cells respond to an apoptotic inducer, we next evaluated whether CerS6 was differentially expressed between NCI cell lines showing an epithelial-or mesenchymal-like gene signature. 23 An in silico analysis performed on tumor cell lines classified as epithelial-or mesenchymal-like cells according to their expression levels of E-cadherin (epithelial marker) and Vimentin (mesenchymal marker) confirmed that the level of CerS6 transcripts was reduced in mesenchymal-like cancer cells as compared with their counterparts exhibiting an epithelial-like gene signature (Supplementary Figure S1 ). To confirm that CerS6 expression was downregulated during EMT, we first evaluated the protein expression levels of two EMT markers, namely, E-cadherin and Vimentin, in 47 NCI-60 tumor cell lines (Supplementary Figure S2A ) that have previously been reported to display an epithelial-or mesenchymal-like phenotype. 24 We ranked these tumor cells based on their E-cadherin/Vimentin ratio ( Figure 2b ) into three groups: (i) an epithelial group with high E-cadherin expression, (ii) an undefined group that either expressed equally the two markers or did not express them, and (iii) a mesenchymal group with high Vimentin expression ( Figure 2b ). Minor differences were found when we compared our classification with the one from Peter's group. 24 Indeed, among the 47 tumor cell lines tested, only five of them (OSCAR-5, PC3, SW620, SR and IGROV-1) showed a difference of classification between the two studies. The protein expression levels of CerS6 were significantly increased in epithelial cells as compared with mesenchymal tumor cells ( Figure 2c ). This suggests that CerS6 is a novel EMT-regulated gene, the expression of which in epithelial cells may alter the SL composition of plasma membranes.
To confirm that CerS6 expression was regulated during EMT, the level of CerS6 expression was evaluated in various wellestablished EMT models. Primary human mammary epithelial cells (HMECs) were used that have undergone sequential retroviral infections to express the telomerase catalytic subunit (hTERT), the large-T and small-t antigens of SV40, and the oncogenic allele of H-Ras (H-Ras V12 ), and have thereby been converted to aggressive tumor cells. 25, 26 This stepwise EMT cellular model system, which gives rise to mammary cells exhibiting epithelial-(E-cadherin) or mesenchymal-like (Vimentin) gene signatures, confirmed that CerS6 expression was extinguished during EMT ( Figure 2d ). To confirm this, CerS6 expression was evaluated in the immortal human mammary epithelial cell line MCF10A and its K-Ras V12expressing counterpart. Expression of the mesenchymal marker N-cadherin (CDH-2) was higher and expression of the epithelial marker E-cadherin was lower in MCF10A-K-Ras V12 cells than in MCF10A cells, consistent with the former cells having undergone EMT (Supplementary Figure S2B and Morel et al. 27 ). Interestingly, EMT triggered by K-Ras V12 expression was accompanied by a decrease in the protein level of CerS6 (Supplementary Figure S2B ). Stimulation with transforming growth factor-β can trigger MCF10A and HMEC-TR breast epithelial cells to undergo EMT. 28 This inducible EMT model was used to establish that CerS6 expression is consistently reduced during EMT (Supplementary Figure S2C ).
Breast cancer is a heterogeneous pathology, with tumors being classified into various subtypes based on their genomic and clinical features. 29 Although luminal A and B tumors express epithelial markers, such as E-cadherin, basal-like cancer cells have a mesenchymal-like phenotype and express mesenchymal markers, such as Vimentin and N-cadherin. 30 Importantly, prognosis is poorer in patients with basal breast tumors than in patients with luminal breast tumors, and EMT is associated with tumor aggressiveness and an increased risk of metastatic dissemination in these patients. 30 A meta-analysis of breast cancer patients using the bc-GenExMiner tool 31 showed that CerS6 expression was lower in basal tumors than in luminal tumors (Supplementary Figure S3 ).
Overall, these data strongly support that CerS6 expression is downregulated in tumor cells undergoing EMT.
Overexpression of CerS6 in mesenchymal tumor cells decreases membrane fluidity and inhibits cell motility
To characterize the cellular function of CerS6 during EMT, CerS6 was overexpressed in two mesenchymal breast cancer cells, MDA-MB-231 and MDA-MB-468. Transduction of these cells with a CerS6-encoding retroviral vector generated stable cell populations overexpressing CerS6 (Figure 3a ). Strikingly, CerS6 overexpression did not alter the expression levels of the mesenchymal marker Vimentin or the epithelial marker E-cadherin (Figure 3a) , suggesting that EMT controlled CerS6 expression but not vice versa. Lipidomic analysis using gas chromatography and mass spectrometry showed that CerS6 overexpression significantly increased the C16-ceramide contents of both cell lines ( Figure 3b ). However, this increase did not alter the total ceramide content (Tables 1 and 2), indicating that a compensatory process served to ensure that the total ceramide content did not change in CerS6overexpressing cells. Modulation of CerS6 expression will affect the acyl-CoA pool, which is required for the biosynthesis of glycerophospholipids, including phosphatidylcholine, phosphatidylinositol, phosphatidylserine and phosphatidylethanolamine; therefore, the levels of these lipids were evaluated in MDA-MB-231 cells, MDA-MB-468 cells and their CerS6-overexpressing counterparts. CerS6 overexpression did not significantly affect the glycerophospholipid content (Tables 1 and 2 ). Ceramide can be metabolized to sphingomyelin, the major plasma membrane SL; therefore, sphingomyelin content was also monitored. Whereas CerS6 overexpression did not affect the total amount of sphingomyelin, the level of C16 sphingomyelin was significantly higher in CerS6-overexpressing cells than in control cells (Tables 1  and 2 ). These findings show that CerS6 overexpression leads to the accumulation of C16:0 ceramide, which is metabolized to more complex SLs, such as C16:0 sphingomyelin. CerS6 overexpression slightly, but significantly, reduced basal membrane fluidity ( Figure 3c ) and prevented cl-CD95L-induced membrane fluidization (Figure 3c ). In addition, CerS6 overexpression in these mesenchymal-like breast cancer cells reduced basal and inhibited CD95-mediated cell motility (Figure 3d ). These findings indicate that ectopic CerS6 expression in mesenchymal-like tumor cells increases levels of C16:0 ceramide and its derivative C16:0 sphingomyelin, which in turn reduces membrane fluidity and inhibits cell motility.
Downregulation of CerS6 in epithelial tumor cells enhances membrane fluidity and stimulates cell migration
To confirm that CerS6 reduces membrane fluidity and cell motility, a pharmacological inhibitor was used to perturb CerS6 activity in epithelial-like breast cancer cells, and the effects of this on plasma membrane fluidity and cell migration were determined. Fumonisin B 1 (FB1), a mycotoxin produced by Fusarium moniliforme, selectively inhibits CerS activity. 32 When the epithelial cell line MCF7 was treated with a non-cytotoxic concentration of FB1 for 48 h, basal and CD95-induced membrane fluidity were slightly, but significantly, increased (Supplementary Figure S4A ). In addition, FB1 treatment enhanced basal and CD95-mediated cell migration (Supplementary Figure S4B) . To confirm these data, Data are means ± s.e.m. of three independent experiments (**P o0.01).
Ceramide synthesis hampers cell migration V Edmond et al
CerS6 expression was downregulated in two epithelial breast cancer cells, MCF7 and T47D. These cells were transduced with lentiviruses encoding simultaneously green fluorescent protein (GFP) and short hairpin RNAs targeting different regions of CerS6 mRNA (shCerS6). All MCF7 cells and >80% of T47D cells were infected (GFP-positive) (Figure 4a ). Consistent with the FACS analyses, CerS6 expression was efficiently silenced in MCF7 cells and to a lesser extent in T47D cells following transduction with lentiviruses containing either shCerS6 (Figure 4b ). Furthermore, the reduction in CerS6 expression did not affect the expression of Abbreviation: shRNA, short haipin RNA. Data are means ± s.e.m. of three independent experiments (*P o0.05, **P = 0.05, ***Po 0.01, ****P = 0.06). (Figure 4b) , confirming that CerS6 is not an EMT master regulator gene. Lipidomic analysis showed that downregulation of CerS6 expression in MCF7 and T47D cells did not alter their total ceramide contents (see insets in Figure 4c and Tables 3 and 4) , whereas the level of C16:0 ceramide was significantly reduced (Figure 4c ). By contrast, downregulation of CerS6 expression was associated with a slight increase in the level of C18:0, C20:0, C24:0 or C24:1 ceramide, according to the cell line (Figure 4c ). CerS6 knockdown increased basal and CD95-mediated plasma membrane fluidity (Figure 4d ) and cell migration (Figure 4e ) in these epithelial cancer cells. Of note, the pro-migratory effect of cl-CD95L was less pronounced in shCerS6-treated MCF7 cells than in shCerS6-treated T47D cells (Figure 4d ). This may be because CerS6 expression was downregulated more efficiently in MCF7 cells than in T47D cells (Figure 4b) , which led to a dramatic increase in the basal motility of MCF7 cells that might partially mask CD95-induced cell motility (Figure 4e ). Overall, these findings demonstrate that downregulation of CerS6 expression in epithelial-like tumor cells enhances cell migration without affecting EMT. C16-ceramide, the product of CerS6, reduces membrane fluidity and cell migration Finally, to show that CerS6 overexpression induced cell membrane compaction and thereby inhibited cell migration, we evaluated the impact of its main lipid product, C16-ceramide. To this end, two mesenchymal breast cancer cells were incubated for 24 h with a non-cytotoxic concentration of C16:0 ceramide (Figure 5a) and membrane fluidity and cell motility were analyzed. Although the addition of C16:0 ceramide slightly increased the basal S parameter in these cell lines (Figure 5b) , it completely inhibited the CD95-mediated increase in membrane fluidization (Figure 5b ). More importantly, basal and CD95-mediated migration of mesenchymal breast tumor cells was impaired when they were cultured in a medium containing a non-cytotoxic concentration of C16-ceramide ( Figure 5c ). These results indicate that exogenous C16-ceramide is adsorbed and retained in cell membranes and confirm that an increased level of C16-ceramide, which is observed upon CerS6 overexpression, is instrumental in preventing CD95-mediated membrane fluidization and cell migration.
EMT-related target genes, including E-cadherin and Vimentin

DISCUSSION
EMT is a crucial process in embryonic development that can be partly phenocopied in carcinogenesis, giving rise to aggressive tumors with increased metastatic capacity. In the present study, we demonstrate that CerS6 expression is downregulated during EMT, leading to increased plasma membrane fluidity, which in turn promotes cell migration. Cells undergoing EMT exhibit morphological changes and increased motility, which is linked to striking reductions in the expression of epithelial markers, such as E-cadherin, and enhanced expression of mesenchymal markers, such as Vimentin and N-cadherin. Using pharmacological and genetic approaches, we showed that the level of CerS6 expression does not affect EMT per se. This seems to disagree with data from the Hakomori group showing that pharmacological inhibition of glucosylceramide synthase or the addition of one of its products, gangliotetraosylceramide (Gg4), modulates cell motility and changes the expression ratio of EMT-related genes in various cellular models, including the epithelial breast cancer cell line MCF-7. 33 One explanation for this discrepancy is that the carbohydrate moiety complexity of Gg4 allows it to target other unidentified molecular targets and thereby exert additional effects on EMT compared with C16-ceramide and C16 sphingomyelin. In support of this hypothesis, the ganglioside GM2, whose expression is also decreased by inhibition of glucosylceramide synthase activity, does not reverse transforming growth factor-β-induced EMT of NMuMG cells, whereas Gg4 does. 33 In addition to the carbohydrate moiety, our findings provide insight into the pivotal roles played by the C16:0 fatty acid chain of ceramide and its derivatives in biological functions, such as cell motility.
Okazaki and colleagues recently showed that sphingomyelin impairs CXCL12-mediated cell migration. 34 The current study shows that CerS6 overexpression is associated with an increase in the C16:0 sphingomyelin content; therefore, we cannot exclude the possibility that sphingomyelin contributes to the phenotypes observed. However, given that CD95-mediated membrane fluidization and cell migration are inhibited by pre-incubation with exogenous C16-ceramide for a short period (60 min), C16-ceramide itself likely contributes to the modulation of membrane fluidity and cell motility during EMT.
Glycosphingolipids modulate various cell signaling pathways by regulating the activities of tyrosine kinase receptors, 35, 36 and more specifically, epidermal growth factor receptor. 35 Based on our recent findings showing that cl-CD95L induces a phosphoinositide 3-kinase (PI3K)-driven pro-migratory signaling pathway in mesenchymal breast tumor cells via recruitment of epidermal growth factor receptor, 37 we investigated whether C16-ceramide can prevent this signaling pathway. Analysis of phosphorylation at serine 473 of Akt, a hallmark of PI3K activation, demonstrated that C16-ceramide did not affect the CD95-mediated PI3K signaling pathway (Supplementary Figure S5 ). This indicates that C16-ceramide does not interfere with the initial steps of promigratory CD95-mediated cell signaling. The mechanistic link between CD95L and plasma membrane fluidization remains uncertain and requires further investigation.
Exogenous short-chain ceramides such as C2-ceramide inhibit migration of lung cancer cells in response to nicotine via activation of protein phosphatase 2A. 38 This previous study suggested that C2-ceramide directly affects cell migration. However, the authors did not eliminate the possibility that C2-ceramide that accumulates in the lipid bilayers of pulmonary cells is hydrolyzed by acid ceramidase to form sphingosine that enters the salvage pathway to form new ceramides through the activities of CerS, such as CerS6. In this regard, it would be interesting to investigate the activity of CerS6 in pulmonary epithelial cells exposed to nicotine.
CerS6 expression was modulated in various cancer cell lines with epithelial-or mesenchymal-like gene signatures, in welldefined inducible EMT models, and also in a large panel of women affected by luminal or basal breast cancers (Supplementary Figure  S3 ), which show an epithelial-or mesenchymal-like gene signature, respectively. 30 Accordingly, we predict that in women with aggressive basal breast cancers in which CerS6 is not expressed, a slight increase in the level of C16-ceramide may help to reduce their elevated risk of metastatic dissemination.
MATERIALS AND METHODS
Cell lines
The human cell lines derived from hematological cell lineage (Jurkat, CEM, H9, HL60, SKW6.4, K562, MOLT4, SR) were cultured in RPMI supplemented with 8% (v/v) heat-inactivated fetal calf serum and 2 mM L-glutamine at 37°C in a 5% CO 2 incubator. All other cancer cell lines were cultured in Dulbecco's modified Eagle's medium supplemented with 8% (v/v) heatinactivated fetal calf serum and 2 mM L-glutamine at 37°C in a 5% CO 2 incubator. The NCI-60 collection of human tumor cell lines came from Charles River Laboratories (Wilmington, MA, USA). Other cells were purchased from American Type Culture Collection (LGC Standards, Molsheim, France). The human mammary epithelial cell line MCF10A is spontaneously immortalized but not transformed. MCF10A cells infected with LXSN-K-RasV12 or an empty vector were kindly provided by Dr BH Park (Baltimore, MD, USA). 39 MCF10A cells were grown in Dulbecco's modified Eagle's medium/F12 medium supplemented with 5% horse serum, epidermal growth factor (20 ng/ml), insulin (10 μg/ml), cholera toxin (100 ng/ml) and hydrocortisone (0.5 μg/ml) at 37°C in a 5% CO 2 incubator. HMECs infected with a retrovirus carrying hTERT, Ras and AgT were kindly provided by Dr RA Weinberg (Cambridge, MA, USA). 25 HMECs immortalized by hTERT and Ras were designated HMEC-TR.
In vitro motility assay
Boyden chambers contained membranes with a pore size of 8 μm (Millipore, Molsheim, France). After hydration of the membranes, mesenchymal cells (10 5 cells per chamber) or epithelial cells (3 × 10 5 cells per chamber) were added to the top chamber in low serum (1%)-containing medium. The bottom chamber was filled with low serum (1%)-containing medium in the presence or absence of cl-CD95L (100 ng/ml). Cells were cultured for 24 h at 37°C. To quantify migration, cells were mechanically removed from the top side of the membrane using a cotton-tipped swab, and migrating cells from the reverse side were fixed with methanol and stained with Giemsa. For each experiment, five representative pictures were taken for each insert, then cells were lysed and absorbance at 560 nm correlated to the amount of Giemsa stain was measured.
EPR
Membrane fluidity was determined by a spin-labeling method using EPR, as previously described. 40 Briefly, plasma membranes of living cells were labeled by incubating cells for 15 min at 37°C with 12-doxyl stearic acid (36 μg/ml), a fatty acid with a stable nitroxide radical ring at the C-12 position. Cells were then washed twice with phosphate-buffered saline to remove excess 12-doxyl stearic acid, and EPR spectra of the labeled samples were acquired at ambient temperature on a Bruker Elexsys EPR spectrometer (Bruker, Wissembourg, France) operating at 3509.25 G center field, 20 mW microwave power, 9.86 GHz microwave frequency, 1.77 G modulation amplitude and 100 kHz modulation frequency. Fluidity of the spin-labeled membranes was quantified by calculating the S parameter. An increase in the S parameter reflects a decrease in membrane fluidity and vice versa.
Immunoblotting
Cells were lysed for 30 min at 4°C in lysis buffer (25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid pH 7.4, 1% (v/v) Triton X-100, 150 mM NaCl and 2 mM ethylene glycol tetraacetic acid supplemented with a mixture of protease inhibitors). Protein concentration was determined by the bicinchoninic acid method (Pierce, Rockford, IL, USA) according to the manufacturer's protocol. Proteins were resolved by 8, 10 or 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to a nitrocellulose membrane (GE Healthcare, Buckinghamshire, UK). The membrane was blocked for 15 min with TBST (50 mM Tris, 160 mM NaCl, and 0.05% (v/v) Tween 20, pH 7.4) containing 5% (w/v) dried skimmed milk (TBSTM) and was then incubated overnight at 4°C with the primary antibody diluted in TBSTM. The membrane was washed with TBST and was then incubated with peroxidase-labeled anti-mouse IgG1 or IgG2a (CliniSciences, Nanterre, France) for 45 min. Proteins were visualized using the enhanced chemiluminescence substrate kit (ECL RevelBlOt, Ozyme, Saint Quentin en Yvelines, France).
